These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8258990)

  • 21. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.
    Distler E; Wölfel C; Köhler S; Nonn M; Kaus N; Schnürer E; Meyer RG; Wehler TC; Huber C; Wölfel T; Hartwig UF; Herr W
    Exp Hematol; 2008 Apr; 36(4):451-63. PubMed ID: 18261837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.
    Koehl U; Sörensen J; Esser R; Zimmermann S; Grüttner HP; Tonn T; Seidl C; Seifried E; Klingebiel T; Schwabe D
    Blood Cells Mol Dis; 2004; 33(3):261-6. PubMed ID: 15528141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production.
    Klingemann HG; Neerunjun J; Schwulera U; Ziltener HJ
    Leukemia; 1993 Sep; 7(9):1389-93. PubMed ID: 8371589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lysis of fresh leukemic blasts by interferon-activated human natural killer cells.
    Pattengale PK; Sundstrom C; Yu AL; Levine A
    Nat Immun Cell Growth Regul; 1983-1984; 3(4):165-80. PubMed ID: 6597341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.
    Herr W; Eichinger Y; Beshay J; Bloetz A; Vatter S; Mirbeth C; Distler E; Hartwig UF; Thomas S
    Leukemia; 2017 Feb; 31(2):434-445. PubMed ID: 27479183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation.
    Bruserud O; Ulvestad E
    Cell Immunol; 2000 Nov; 206(1):36-50. PubMed ID: 11161436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HL-60 myeloid leukaemia cells acquire immunostimulatory capability upon treatment with retinoic acid: analysis of the responding population and mechanism of cytotoxic lymphocyte activation.
    Geary SM; Ashman LK
    Immunology; 1996 Jul; 88(3):428-40. PubMed ID: 8774361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
    Linn YC; Hui KM
    Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia.
    Brune M; Hellstrand K
    Br J Haematol; 1996 Mar; 92(3):620-6. PubMed ID: 8616026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
    Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
    Front Immunol; 2018; 9():977. PubMed ID: 29780393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adhesion molecules on MHC-nonrestricted lymphocytes: high density expression and role in oncolysis.
    Savary CA; Lotzová E
    Lymphokine Cytokine Res; 1992 Jun; 11(3):149-56. PubMed ID: 1391234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
    Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
    Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell-mediated cytotoxicity as a result of immunotherapy in patients with acute myeloid leukaemia.
    Taylor GM; Harris R; Freeman CB
    Br J Cancer; 1976 Feb; 33(2):137-43. PubMed ID: 1063029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
    Boyiadzis M; Agha M; Redner RL; Sehgal A; Im A; Hou JZ; Farah R; Dorritie KA; Raptis A; Lim SH; Wang H; Lapteva N; Mei Z; Butterfield LH; Rooney CM; Whiteside TL
    Cytotherapy; 2017 Oct; 19(10):1225-1232. PubMed ID: 28864289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy?
    Bruserud Ø; Wendelboe Ø
    Expert Opin Biol Ther; 2001 Nov; 1(6):1005-16. PubMed ID: 11728232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
    Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells.
    Perussia B; Chan SH; D'Andrea A; Tsuji K; Santoli D; Pospisil M; Young D; Wolf SF; Trinchieri G
    J Immunol; 1992 Dec; 149(11):3495-502. PubMed ID: 1358972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of imipenem and cilastatin on human T-lymphocytes derived from acute leukemia patients with chemotherapy-induced leucopenia: studies of T-lymphocyte responses in the presence of acute myelogenous leukemia (AML) blast accessory cells.
    Bruserud O
    Int J Immunopharmacol; 2000 Jan; 22(1):69-81. PubMed ID: 10684990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The CD226-ERK1/2-LAMP1 pathway is an important mechanism for Vγ9Vδ2 T cell cytotoxicity against chemotherapy-resistant acute myeloid leukemia blasts and leukemia stem cells.
    Wu K; Wang LM; Liu M; Xiu Y; Hu Y; Fu S; Huang H; Xu B; Xiao H
    Cancer Sci; 2021 Aug; 112(8):3233-3242. PubMed ID: 34107135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
    Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
    Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.